isabelobrien, Author at European Medical Journal - Page 7 of 65

Sara Tolaney

Onc Now: Episode 25: From Trials to Treatment in Breast Cancer Care

Sara Tolaney shares insights on breast cancer care, including her research on CDK4/6 inhibitors and exploring ways to de-escalate treatment.

MSD strikes $10bn deal for Verona Pharma

MSD has agreed to acquire UK biopharma company Verona Pharma in a $10bn deal, strengthening its cardio-pulmonary care portfolio.

Rising STEM stars take home Thermo Fisher Award

A group of 300 middle schoolers are named in the 2025 Thermo Fisher Junior Innovators Challenge for STEM projects in AI to climate change.

Andrew Dunbar

Hema Now: Episode 24: Understanding Myeloproliferative Neoplasms

What are myeloproliferative neoplasms, and what can research reveal about future therapies? Andrew Dunbar explores the biology, resistance, and emerging treatment strategies.

How to thrive, and not just survive, at congress

As pharma invests millions in congress presence, the pressure to cut through crowded halls and fleeting interactions has never been higher.

Gold coins on blue background

Newcastle University wins £22m UK's NIHR health tech award

The National Institute for Health and Care Research (NIHR) is funding Newcastle Univeristy’s work in emerging diagnostics, devices and more.

British government buildings

UK government establishes RNA Biofoundry

A £29.6 million government investment will establish the UK RNA Biofoundry in Darlington, providing manufacturing capacity to accelerate RNA therapies from lab to clinic.

A collection of illustrated lab equipment

Novo Nordisk taps Replicate’s srRNA platform for obesity

Novo Nordisk partners with Replicate Bioscience in a $550M srRNA deal to develop new therapies for obesity, diabetes and cardiometabolic diseases.

The word spotlight on a blue background

Spotlight: August 2025

From the latest in clinical evidence to new investments, there’s plenty to uncover.

Psychedelic pattern

AbbVie expands pipeline with psychedelic therapy

AbbVie has announced the acquisition of Gilgamesh Pharmaceuticals’ lead investigational drug – a next-generation psychedelic compound for moderate-to-severe major depressive disorder.